Przemysław Borowy

Dr. Przemysław Borowy

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2013 in Ortopedia Traumatologia Rehabilitacja
Verified
Journal Article
Closed access
ECEdward Czerwiński
Edward Czerwiński
PBPrzemysław Borowy
Przemysław Borowy
AKAnna Kumorek
Anna Kumorek
JAJarosław Amarowicz
Jarosław Amarowicz
MGMaciej Górkiewicz
Maciej Górkiewicz
AMAgata Milert
Agata Milert
FRAX is a an algorithm accepted by WHO for evaluating fragility fracture risk of women aged 40 years or more. The aim of this study was to use the FRAX tool to verify the risk of fractures in a population of women from the Cracow region in an 11-year follow-up. The study was a retrospective cohort survey evaluating the incidence of fragility fractures over 11 years of follow-up. 5,092 women aged 50 years and more were randomly chosen from a group of 100,000 female patients of the Cracow Medical Centre who came to the Centre for densitometric examination between 1997 and 2001. Finally, 1024 patients were randomized into the study. After an average of 11 years a follow-up telephone survey was conducted among a randomly selected group of patients using a questionnaire corresponding to the one applied in the first survey. 10-year fracture risk was calculated for each patient using FRAX based on the BMI (Body Mass Index) and for 886 women using FRAX based on BMD (Bone Mineral Density) at the femoral neck. The Polish version of FRAX was validated by comparing the predicted risk with the actual incidence of fractures during the 11-year follow-up. The 10-year probability of a major osteoporotic fracture calculated using FRAX based on BMI for the entire group was 5.3% (median, 1st/3rd quartile: 3.5-8.5%) and the probability of a proximal femur (hip) fracture was 1.3% (median, 1st-3rd quartile: 0.7% -2.4%). In 886 women whose BMD T-score at the femoral neck was available, the mean probability of a major osteoporotic fracture was 4.9% (3.3-7.9%) and of a hip fracture 0.9% (0.3-2.3%). The actual absolute fracture risk calculated on the basis of the number of patients who had experienced a fracture during the follow-up was surprisingly much higher than the predicted figure. The risk of a major fracture in the study group was 17.7% and of a proximal femur fracture, 3%. In our opinion, FRAX is a very good screening tool, but not a precise diagnostic tool.

1 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
PBPrzemysław Borowy
Przemysław Borowy
BBBogdan Batko
Bogdan Batko
AKAlicja Kamińska
Alicja Kamińska
PMPatrycja Major
Patrycja Major
KGKatarzyna Gołojuch
Katarzyna Gołojuch
ECEdward Czerwiński
Edward Czerwiński
Background: Bone mineral density (BMD) assessed by DXA is a well-established predictor of osteoporotic fracture risk. However, data regarding the Polish female population remains limited. Objective: To evaluate the predictive value of BMD measurements for vertebral, hip, and all low-energy fractures in women aged 50 years and older. Methods: A total of 1.311 women from the Małopolska region underwent BMD assessment at the femoral neck, lumbar spine. The average follow-up period was 10.2 years, during which 479 osteoporotic fractures were recorded. Results: DXA measurements at the femoral neck showed the strongest correlation with hip fracture risk. Each one standard deviation decrease in the femoral neck T-score increased the risk of hip fracture by 2.1 times (HR 2.10; 95% CI 1.28–3.46; p = 0.003), after adjusting for age, but is not linear. A 1 SD decrease in the hip T-score was associated with a 28% increase in the risk of all osteoporotic fractures (HR 1.28; CI 1.17–1.40; p < 0.001), 53% increase in vertebral (HR 1.53; CI 1.13–2.08; p = 0.006) and 30% in hip (HR 1.30; CI 0.81–2.09; p = 0.278). The AUC values for hip BMD and hip T-score had the highest predictive value—AUC (area under the curve was 0.732 and 0.720, p < 0.01). Conclusions: BMD at the femoral neck proved to be a stronger predictor of hip fractures than measurements at the spine, radius. The risk increase associated with BMD/T-score reduction was non-linear. These findings confirm results from other benchmark studies.

4 March 2025 in Central European Journal of Immunology
Verified
Journal Article
Open access
PBPrzemysław Borowy
Przemysław Borowy
AKAlicja Kamińska
Alicja Kamińska
PMPatrycja Major
Patrycja Major
JSJakub Smyk
Jakub Smyk
KGKatarzyna Gołojuch
Katarzyna Gołojuch
BBBogdan Batko
Bogdan Batko
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease whose treatment is still a challenge. The latest registration of anifrolumab for the treatment of moderate-to-severe SLE raises hopes because of its novel anti-interferon mechanism of action. Anifrolumab, a human monoclonal antibody, selectively binds the interferon α (INF-α) receptor, inhibiting systemic inflammation moderated by interferon pathways. The article presents the first case of an 18-year-old man with severe, relapsing and repeatedly hospitalized SLE, successfully treated with anifrolumab. During a subsequent exacerbation with multi-organ involvement, which could not be controlled despite pulses and high doses of glucocorticoids (GCSs), treatment with anifrolumab was initiated. Clinical improvement was achieved 4 weeks after the first dose. The patient’s dose of systemic GCSs was gradually reduced until complete withdrawal. No serious side effects were observed throughout the follow-up period, and the criteria for complete remission were achieved by the patient at month 3 of therapy. After 12 months, therapy was discontinued due to a payer decision. Nevertheless, the patient remains in follow-up 14 months after the completion of therapy on stable treatment with hydroxychloroquine and azathioprine. He is still not taking prednisone. This is the first case in Poland to show the fate of a “real life patient” after completion of anifrolumab therapy, an effective clinical remission of many months without the use of oral GCSs.

9 July 2024 in Hematology in Clinical Practice
Verified
Journal Article
Open access
PDF file
AKAlicja Kamińska
Alicja Kamińska
KGKatarzyna Gołojuch
Katarzyna Gołojuch
PMPatrycja Major
Patrycja Major
JSJakub Smyk
Jakub Smyk
PBPrzemysław Borowy
Przemysław Borowy
BBBogdan Batko
Bogdan Batko
Systemic mastocytosis (SM) is a rare hematologic neoplastic disorder characterized by infiltration of various organs by clonal mast cells. It s characterized with cutaneous and organ involvement (hepatosplenomegaly, osteolytic changes, pathological fractures) and systemic symptoms related to the release of anaphylaxis mediators. Systemic mastocytosis was diagnosed in a 50-year-old patient based on WHO criteria. The disease course included fractures of the TH11 and L1 vertebrae, and densitometric tests revealed low bone mineral density (BMD). The patient was treated with risedronate for 3 years, yet BMD continued to decline. The therapy was switched to intravenous zoledronic acid, resulting in a significant increase in BMD in control tests and relief from pain. No new osteoprotic fractures were observed during the treatment. Keywords: mastocytosis osteoporosis treatment bisphosphonates

1 January 2024 in Dermatology Review
Verified
Journal Article
Open access
PDF file
PBPrzemysław Borowy
Przemysław Borowy
OWOlga Wcisłek
Olga Wcisłek
JPJulia Płonczyńska
Julia Płonczyńska
MHMateusz Heba
Mateusz Heba
BBBogdan Batko
Bogdan Batko
Bullous pemphigoid (BP) is a chronic autoimmune skin disease. It is characterized by the presence of well-tense blisters in the area of erythematous-oedematous eruptions, as well as in the unaffected skin that often develops lesions triggered by medications or focal points. The treatment involves...

30 July 2025 in European Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
PBPrzemysław Borowy
Przemysław Borowy
KUKarol Urbański
Karol Urbański
KGKatarzyna Gołojuch
Katarzyna Gołojuch
PMPatrycja Major
Patrycja Major
JSJakub Smyk
Jakub Smyk
JSJoanna Szpor
Joanna Szpor
Neutrophil dermatitis is a group of diseases characterized by the leakage of neutrophils in the skin and subcutaneous tissue with a non-infectious, autoinflammatory etiology. These include the aseptic abscess syndrome (AA). Diagnosis is based on histopathological examination and the exclusion of infectious, allergic, and cancer causes. The paper presents the case of a 41-year-old woman with inflammatory spondyloarthropathy (HLA-B27 antigen present), treated with secukinumab, who developed a painful, inflammatory tumor in her right breast. Antibiotic treatment was ineffective, and histopathological examination detected leaching mainly from granulocytes. Infectious and oncological background changes and IgG4+ disease were excluded. After the diagnosis was confirmed, glucocorticoid therapy was started, which brought rapid improvement, but after the dose was reduced, the tumor relapsed. The re-escalation of the steroid dose and the discontinuation of secukinumab coincided with the exacerbation of ankylosing spondylitis, which forced the inclusion of upadacitinib, which was effective and well tolerated. Single studies show high efficacy of TNF inhibitors as well as IL-6 or IL-1 blockades in the treatment of AA and secondary prevention in patients with failed steroid therapy. There are no reports of AA cases in the literature during treatment with secukinumab. Treatment with upadacitinib has so far not caused AA recurrence. Cite this article as: Borowy P, Urbański K, Gołojuch K, et al. Aseptic abscess associated with ankylosing spondylitis—cause or effect of therapy? Case report.Eur J Rheumatol. 2025, 12(3), 0079, doi:10.5152/eurjrheum.2025.24079.